<DOC>
	<DOCNO>NCT02584465</DOCNO>
	<brief_summary>The objective randomized phase II evaluate benefit regorafenib ovarian patient report confirmed elevated CA-125 level surveillance bevacizumab , compare tamoxifen .</brief_summary>
	<brief_title>REGorafenib vsTamoxifen Patients With Platinum-sensitive OVARian Carcinoma Isolated Biological Progression</brief_title>
	<detailed_description>- After surgery , patient advance ovarian/primitive peritoneal /fallopian carcinoma receive first line treatment , carboplatin plus paclitaxel plus minus bevacizumab 6 cycle follow surveillance bevacizumab maintenance therapy one year ( GOG ( Burger et al . ) , ICON7 ( Perren et al . ) , French national guideline Saint Paul de Vence ( www.arcagy.org ) ) . - This multi-modality approach achieve clinical response 70 % patient , although majority woman eventually relapse die disease progression . The first sign relapse progressively rise CA-125 ( Tuxen et al. ) . - Biochemical-recurrent Epithelial Ovarian Cancer ( EOC ) define CA-125 elevation normal value without clinical evidence disease , predate clinical disease approximately 3-6 month ( Tuxen et al. ) . Even CA-125 elevation harbinger EOC relapse , question remain whether early therapeutic intervention translate extend duration survival . - A year ago , Rustin report ovarian cancer patient surveillance first line treatment isolate elevated CA-125 ( without RECIST/symptoms criterion ) benefit initiate new chemotherapy compare surveillance ( Rustin et al . Lancet 2010 ; Rustin et al . Ann Oncol 2011 ) . - For patient bevacizumab maintenance phase time CA-125 elevation without RECIST symptom progression , data scare . In GOG0218 trial , elevate CA-125 totally comply RECIST criterion progression . This study report median PFS longer patient continuous bevacizumab ( 14.1 month ) , compare patient placebo ( 10.3 month ) , use CA-125 &amp; RECIST criterion , support hypothesis maintenance treatment anti angiogenic agent allow delay disease progression ( Burger et al . N. Engl . J. Med . 2011 ) . In analysis progression-free survival data patient increase CA-125 level censor , median progression-free survival 12.0 month control group 18.0 month bevacizumab-throughout group ( hazard ratio , 0.645 ; P &lt; 0.001 ) . The relationship CA-125 progressive disease ( PD ) may alter bevacizumab ( BV ) -treated patient . In Ocean trial elevate CA-125 associate forthcoming progression majority patient bevacizumab ( HR 0.48 ) platinum sensitive population ( Aghajanian et al. ) . - Current international recommendation continue strategy ( surveillance maintenance bevacizumab ) RECIST symptomatic progression regardless CA-125 level . - However , argue wait attitude deem unacceptable due patient anxiety rise CA-125 compelling significant proportion physician propose therapeutic intervention , due nearness disease progression . - Tamoxifen endocrine alternative treatment option patient rise CA-125 . Hurteau et al . study support use tamoxifen show 17 % response rate measurable recurrent disease , 13 % response rate platinum resistant disease , observe stable disease 38 % patient last median 3 month ( Hatch , et al ) . - The use tamoxifen treatment control arm isolate CA-125 thus justify base favorable toxicity profile compare available cytotoxic agent lack interference subsequent intervention beyond documentation clinical progression ( Marckman , et al ) . As patient today benefit introduce new chemotherapy regimen isolate elevated CA-125 ( Rustin et al 2010 ) , explore new anti-angiogenic agent could clinically relevant . Agents inhibit tumor angiogenesis invasion consider ideal candidate experimental arm give potential prolong duration disease-free survival exhibit favorable toxicity profile cytotoxic drug . - Pazopanib multi-kinase inhibitor cediranib , nintenanib report activity relapse ovarian cancer ( sensitive resistant population ) use alone several phase II trial ( Matulonis et al. , Ledermann et al. , Friedlander et al. ) . - Regorafenib new oral multi-kinase inhibitor . It inhibit kinase involve angiogenesis ( VEGFR 1-3 , TIE 2 ) , signal tumor microenvironment ( PDGFR-β , FGFR ) oncogenesis ( KIT , RET BRAF ) . Inhibition tumor growth formation metastases show vivo . Tumor activity report variety tumor type . Regorafenib approve Europe treatment metastatic colorectal cancer patient previously treat , consider candidate , available therapy . An application GIST progress imatinib sunitinib obtain AMM Europe . The recommend dose 160 mg take daily 3 week follow 1 week therapy . The objective randomized phase II evaluate benefit regorafenib ovarian patient report confirmed elevated CA-125 level surveillance bevacizumab , compare tamoxifen .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Main I2 Histological confirmation epithelial ovarian , fallopian tube , primary peritoneal cancer , I3 Rising CA125 ( accord Rustin/GCIG criterion , see appendix 10 ) ) occur 6 month last platinumbased chemotherapy cycle ( platinum sensitive ) , I4 No symptom relate ovarian cancer progression , I6 1 2 prior line platinumbased chemotherapy follow either surveillance bevacizumab maintenance , I7 Before randomization , patient must CR , PR SD ( RECIST version 1.1 ) surveillance maintenance bevacizumab , I8 Adequate bone marrow , liver renal function assess follow laboratory test conduct within 7 day randomization : Absolute Neutrophil Count ≥ 1.5 G/L , platelets count ≥ 100 G/L , hemoglobin ≥ 9g/dL , AST/ALT ≤ 3 x upper limit normal ( ULN ) ( ≤ 5.0 x ULN liver metastasis ) total bilirubin ≤ 1.5 x ULN , Alkaline phosphatase ≤ 2.5 x ULN Serum creatinine ≤ 1.5 x ULN , Glomerular filtration rate ( GFR ) ≥ 30 mL/min/1.73 m² accord Modification Diet Renal Disease ( MDRD ) abbreviate formula Lipase ≤ 1.5 x ULN Prothrombine timeinternational normalize ratio ( PTINR ) &lt; 1.5 x ULN . Patients therapeutically anticoagulated agent warfarin heparin allow participate provide prior evidence underlie abnormality parameter exists , I9 Women childbearing potential partner must agree use adequate contraceptive method ( previous bilateral annexectomies ) whole study period 6 month last dose study treatment ; negative pregnancy test must obtain prior randomization , Main E4 Past concurrent history neoplasm ovarian cancer , except situ carcinoma cervix uterus , situ breast cancer and/or basal cell epithelioma . All treats cure cancer 3 year study entry allow E5 Known history symptomatic metastatic brain meningeal tumor ( head CT MRI screen confirm absence central nervous system ( CNS ) disease patient symptom suggestive consistent progressive CNS disease ) , E6 Any prior radiotherapy pelvis abdomen ; surgery ( include open biopsy ) within 4 week start study drug ( 24 hour minor surgical procedure ) , plan major surgery study treatment period , E7 Any prior treatment anti angiogenic agent pazopanib , nintedanib cediranib . Patients previously treat bevacizumab allow include , E8 Endocrine therapy administer within 3 year prior randomization , E13 History follow : abdominal fistula , gastrointestinal perforation , intraabdominal abscess , malabsorption condition , E14 Clinically significant bleeding NCICTCAE version 4.3 Grade 3 high within 30 day randomization , E15 Congestive heart failure New York Heart Association ( NYHA ) ≥ class 2 , E17 Uncontrolled hypertension ( systolic blood pressure ( BP ) &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) , E21 Ongoing infection &gt; Grade 2 accord NCICTCAE version 4.3 . Hepatitis B allow active replication present . Hepatitis C allow antiviral treatment require , E23 Interstitial lung disease ongoing sign symptoms time screening ,</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>